SEQUENTIAL THERAPY WITH MOVALIS IN PATIENTS WITH COCCYGODYNIA
- Authors: Vlaskin S.I.1, Vlaskin SI1
-
Affiliations:
- Issue: No 9 (2011)
- Pages: 71-74
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/278888
- ID: 278888
Cite item
Full Text
Abstract
Coccygodynia is characterized by persistent pain in the coccyx that provides dramatically negative impact on quality of life of patients. The article presents the results of examination and treatment of 45 patients with coccygodynia who were treated with drug Movalis (meloxicam) used in stepwise scheme (intramusculary - per os 15 mg/day, 13 days). The high efficacy and safety of Movalis in the treatment of coccygodynia were observed: good and excellent effect was achieved in about ¾ of patients, adverse events were absent.
References
- Попелянский Я.Ю. Вертеброгенные заболевания нервной системы. Т.2: Пельвиомембральные синдромы поясничного остеохондроза. Йошкар-Ола, 1983. С. 372.
- Баркан М.Б. О кокцигодинии // Клиническая медицина. 1980. № 1. С. 96.
- Fogel GR, Cunningham PY, Esses SI. Coccygodynia: evaluation and managment. J Am Acad Orthop Surg 2004;12(1):49-54.
- Ramsey ML, Toohey JS, Neidre A, et al. Coccygodynia: treatment. Orthopedics 2003:26(4):403-05.
- Maigne JY, Guedj S, Straus C. Idiopathic coccygodynia. Lateral roentgenograms in the sitting position and coccygeal discography. Spine 1994;19(8):930-34.
- McKellar G, Madhoc R, Singh G. The problem with NSAIDS: What data to beleive? Current pain and headacke reports 2007;11(6):423-27.
- Fosbol EL, Kober L, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs among healthy individuals. Expert opinion on drug safety 2010;9(6):893-903.
- Потапова И.С., Дударева А.А. с соавт. Опыт применения препарата Мовалис при спондилолистезе и кокцигодинии у детей. В сб: Актуальные проблемы заболеваний и повреждений опорно-двигательного аппарата детского возраста. Барнаул, 2010. C. 27-29.
- Hawkey C, Kahan A,et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. Br J Rheumatol 1998;37:937-45.
- Schoenfeld P. Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials. Am J Med 1999;107:48-54.
- Layton D, et al. Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data. Rheumatol 2003;42:1354-64.
- Bevis PJR, Bird HA, et al. An open study to assess the safety and tolerability of meloxicam 15 mg in subjects with rheumatic disease and mild renal impairment. Br J Rheumatol 1996;35(1):56-60.
- Winkelmayer WC, Waikar SS, et al. Nonselective Cyclooxygenase-2-Selective NSAIDs and Acute Kidney Injury. Am J Med 2008;121(12):1092-98.
Supplementary files
